Loading…
Go to symposium website → www.slas.org/HighContentAnalysis
Tuesday, October 22 • 3:10pm - 3:30pm
Complex Translational Models- Metastatic Colorectal Cancer Organoids as a Novel Model System for Personalized Medicine and Reverse Translation

Sign up or log in to save this to your schedule and see who's attending!

Regorafenib has shown anti-cancer activity in metastatic colorectal cancer (mCRC) patients by inhibiting tumor vasculature. A mCRC PDO model can mimic tumor-stroma interaction for improving patient selection and measure drug resistance. In this work, we recapitulated clinical response in vivo, and compared to the ex vivo tumor-stroma model. A translational phase II trial of regorafenib in chemo-refractory mCRC patients with biopsiable metastases was conducted. For the in vivo models, PDOs were implanted in livers of NSG mice and treated with regorafenib. The Ex vivo model was generated by co-culturing PDOs with CAFs and EC. PDOs retained genomic and transcriptomic features of parental biopsies. The results showed vascular density reduction after regorafenib treatment in mice from responders’ patients, and no significant changes in non-responders. The developed PDO co-cultures resembled the metastatic niche predicting response to anti-cancer treatments to inform clinical decisions.

Co-Authors:
1 Georgios Vlachogiannis
2 Andrea Lampis
3 Khurum Khan
4 David Cunningham
5 Matteo Fassan
6 Ruwaida Begum
7 Leo Chan
8 Ning Lai
9 Reem Eldawud
10 Nicola Valeri

Speakers
avatar for Somaieh Hedayat

Somaieh Hedayat

Ph.D. student, Institute of Cancer research
Patient-derived organoids (PDOs) have recently emerged as robust preclinical models. We have recently shown that PDOs from metastatic, heavily pretreated, colorectal and gastroesophageal cancer patients mirror the phenotype and the genotype of their parental biopses and recapitulate... Read More →

Chair
TS

Timothy Spicer, BS, MS, Ph.D.

Senior Scientific Director, Scripps Research Florida


Tuesday October 22, 2019 3:10pm - 3:30pm
Wellcome Auditorium